Whole–genome characterization of chemoresistant ovarian cancer
Top Cited Papers
- 27 May 2015
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature
- Vol. 521 (7553), 489-494
- https://doi.org/10.1038/nature14410
Abstract
Patients with high-grade serous ovarian cancer (HGSC) have experienced little improvement in overall survival, and standard treatment has not advanced beyond platinum-based combination chemotherapy, during the past 30 years. To understand the drivers of clinical phenotypes better, here we use whole-genome sequencing of tumour and germline DNA samples from 92 patients with primary refractory, resistant, sensitive and matched acquired resistant disease. We show that gene breakage commonly inactivates the tumour suppressors RB1, NF1, RAD51B and PTEN in HGSC, and contributes to acquired chemotherapy resistance. CCNE1 amplification was common in primary resistant and refractory disease. We observed several molecular events associated with acquired resistance, including multiple independent reversions of germline BRCA1 or BRCA2 mutations in individual patients, loss of BRCA1 promoter methylation, an alteration in molecular subtype, and recurrent promoter fusion associated with overexpression of the drug efflux pump MDR1.Keywords
This publication has 62 references indexed in Scilit:
- Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with BRCA1 and BRCA2 MutationsClinical Cancer Research, 2013
- Clonal evolution of high‐grade serous ovarian carcinoma from primary to recurrent diseaseThe Journal of Pathology, 2012
- Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 InactivationCancer Research, 2012
- Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinomaLaboratory Investigation, 2012
- RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genomeBMC Bioinformatics, 2011
- Secondary Somatic Mutations RestoringBRCA1/2Predict Chemotherapy Resistance in Hereditary Ovarian CarcinomasJournal of Clinical Oncology, 2011
- Ovarian Cancer Development and MetastasisThe American Journal of Pathology, 2010
- Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase InhibitorsClinical Cancer Research, 2010
- Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian CarcinomasClinical Cancer Research, 2009
- Frequency of BRCA1 Dysfunction in Ovarian CancerJNCI Journal of the National Cancer Institute, 2002